Founded in 1995 and based in Muggia, Italy, WiQo’s patent-protected flagship product, PRX-T33 is the world’s only needle-free chemical stimulation treatment for skin rejuvenation. The company was founded by Dottoressa Castallana and her husband and is the result of 20 years of dermatologic practice. WiQo’s products are distributed in over 45 countries on 5 continents through some 40,000 skin care professionals, including dermatologists, plastic surgeons, aesthetic physicians and medspa operators.

Archimed, a French private equity fund with a strong track record in the healthcare sector, has been chosen among numerous industrial options (EU and extra EU).

Cross Border supported the founding shareholders in the search of a strategic partner to support and accelerate future growth of the company and parlay global presence into global dominance. Cross Border managed the entire sale process, as exclusive advisor, starting from the selection of possible counterparties, through the preparation of documentation for investors and at last assisting WiQo in structuring the transaction, in the due diligence and in the negotiation.

The deal is a long-term partnership aimed at highly ambitious growth. Castellana and her family have rolled a significant portion of their proceeds from the all-equity deal back into WiQo, retaining 25 percent.

Castellana will remain with WiQo, focusing on research & product development.

PRESS RELEASE:

Legal Community: WiQo – Archimed
Milano Finanza: WiQo – Archimed
Il Sole 24Ore: WiQo – Archimed